. Author manuscript; available in PMC: 2010 Sep 1.

Published in final edited form as: Cancer Lett. 2010 Mar 19;295(1):69–84. doi: 10.1016/j.canlet.2010.02.015

Table 2.

Inhibitory effect induced by gemcitabine treatment on the cell cycle progression of pancreatic cancer cells.

Cell type/tested agent	Cell population in cell cycle phases (%)^a
Cell type/tested agent	^bG1/early S	S	G₂/M
CD18/HPAF-Src
0 nM Gemcitabine	61.3 ± 1.7	26.4 ± 2.4	12.3 ± 0.8
10 nM Gemcitabine	63.6 ± 0.5	26.0 ± 0.2	10.7 ± 0.7
20 nM Gemcitabine	68.1 ±1.2	21.4 ± 1.3	10.5 ± 0.2
50 nM Gemcitabine	74.4 ±0.7	15.9 ± 0.3	10.7 ± 0.3
100 nM Gemciabine	82.4 ± 0.6	8.4 ± 0.2	9.2 ± 0.4
CD18/HPAF-shMUC4
0 nM Gemcitabine	66.1 ± 0.7	19.3 ± 0.4	14.6 ± 0.4
10 nM Gemcitabine	74.7 ±1.1	15.5 ± 0.3	9.8 ± 1.2
20 nM Gemcitabine	83.2 ±1.8	11.6 ± 0.5	5.1 ± 0.3
50 nM Gemcitabine	85.5 ±1.8	7.9 ± 0.7	6.6 ± 2.0
100 nM Gemciabine	91.8 ± 0.8	4.8 ± 0.8	3.4 ± 0.1

Data represent the percentage of cells in cell cycle phases observed after 2 days of treatment with indicated gemcitabine concentrations as estimated by the cell counts following FACS analyses. Data are means ± S.E. of 3–6 different experiments.